Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Strong-Buy at Roth Capital

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Friday. Finally, Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday. They issued a “buy” rating and a $7.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $11.25.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $1.88 on Friday. The firm has a market cap of $62.87 million, a PE ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $4.83. The firm has a 50 day simple moving average of $1.56 and a 200 day simple moving average of $1.29.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities and Exchange Commission. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.